10-K · February 24, 2026
Globus Medical reported a strong Q4 2025 quarter with revenue of $826.42M and GAAP diluted EPS of $1.28, reflecting margin expansion (gross margin 68.4%, operating margin 20.5%) and robust free cash flow of $202M in the…
Earnings analysis · 10-Q
GMED earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Globus Medical reported a strong performance for Q1 2026, showcasing a notable increase in revenue and EPS compared to both the prior quarter and year. Total net sales rose by 27.0% to approximately $759.9 million,…
Read full summary
Globus Medical reported a strong performance for Q1 2026, showcasing a notable increase in revenue and EPS compared to both the prior quarter and year. Total net sales rose by 27.0% to approximately $759.9 million, while diluted EPS improved by 107.4% to $1.12, exceeding market expectations.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.12
- Gross margin
- 30.8%
- Segment
- Musculoskeletal Solutions
- Segment
- Enabling Technologies
What stood out
-
Revenue Growth Exceeds Expectations
Actual revenue for Q1 2026 rose to $759.9 million, surpassing estimates by 2.86%.
-
Significant EPS Beat
The diluted EPS stood at $1.12, beating the estimate of $0.92 by 21.74%.
-
U.S. and International Sales Up
U.S. net sales increased by 25% to $604.9 million; international sales rose by 35.6% to $155 million.
-
Improved Gross Margin
Gross margin improved to 30.8% in Q1 2026 from 32.7% in Q1 2025.
-
Strong Operating Cash Flow
Operating cash flow rose to $202.4 million, up from $177.3 million, reflecting a $25.1 million increase.
-
Increased Investment in R&D
R&D expenses rose by 10.4% to $36.5 million, highlighting commitment to innovation.
What to watch
-
Rising Acquisition Costs
Acquisition-related costs spiked by 503% to $6.4 million due to fair value changes.
-
Increased SG&A Expenses
Selling, general and administrative expenses grew by 22.6% to $297.8 million, driven by Nevro-related costs.
-
Cash Flow Variability
Investing activities saw a net outflow of $182.7 million, a significant increase from the prior year.
Management's outlook
No explicit numeric guidance provided; management indicates continued growth expectations.
Earlier filings 4
10-Q · November 5, 2024
Globus Medical reported strong Q3 results: net sales of $625,705,000 (Q3 2024) vs $383,639,000 (Q3 2023) and diluted EPS of $0.38 (Q3 2024) vs $0.01 (Q3 2023). Operating income widened to $48,098,000 in the quarter and…
10-Q · August 6, 2024
Revenue jumped sharply to $629,691 (in thousands) in Q2 2024 versus $291,615 in Q2 2023 (a $338,076 increase), driven by the NuVasive merger, but margin pressure and elevated acquisition/amortization and operating costs…
10-Q · November 8, 2022
Globus Medical reported Q3 net sales of $254,148,000, up 10.6% year-over-year from $229,721,000, with gross profit of $188,651,000 and operating income of $59,702,000. Diluted EPS was $0.47 (vs $0.45 in Q3 2021).…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.